Avita Medical Inc.

06/05/2025 | Press release | Distributed by Public on 06/05/2025 14:36

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Panaccio Lou
2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [RCEL]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O AVITA MEDICAL 28159 AVENUE STANFORD, SUITE 220
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2025
(Street)
VALENCIA, CA 91355
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2025 A 10,022 A (1) 56,428(2)(3) D
Common Stock 5,972(4) I See footnote(5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $8.73(6) 01/21/2025 A 4,295 01/21/2026 01/21/2035 Common Stock 4,295 $ 0 4,295 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Panaccio Lou
C/O AVITA MEDICAL 28159 AVENUE STANFORD
SUITE 220
VALENCIA, CA 91355
X

Signatures

/s/ Nicole Kelsey, by power of attorney 06/05/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.
(2) Includes unvested RSUs.
(3) Includes 70,460 of the Issuer's CDIs. The Reporting Person holds 70,460 CDIs, which translate into 14,092 of the shares of Common Stock set forth above.
(4) Reflects 29,860 CDIs, which translate into the 5,972 shares of Common Stock set forth above.
(5) These CDIs are held by The Panaccio Superannuation Fund (the "Fund"). The Reporting Person is a director of Tercus Pty Ltd, trustee of the Fund, and is a beneficiary of the Fund. The Reporting Person may be deemed to have shared voting and dispositive power over the CDIs held by the Fund but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein.
(6) On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Avita Medical Inc. published this content on June 05, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 05, 2025 at 20:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io